JP6797825B2 - 気管支肺異形成症を治療する抗ｆｌｔ−１抗体 - Google Patents

気管支肺異形成症を治療する抗ｆｌｔ−１抗体 Download PDF

Info

Publication number
JP6797825B2
JP6797825B2 JP2017552909A JP2017552909A JP6797825B2 JP 6797825 B2 JP6797825 B2 JP 6797825B2 JP 2017552909 A JP2017552909 A JP 2017552909A JP 2017552909 A JP2017552909 A JP 2017552909A JP 6797825 B2 JP6797825 B2 JP 6797825B2
Authority
JP
Japan
Prior art keywords
antibody
flt
antigen
seq
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017552909A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018517667A5 (enExample
JP2018517667A (ja
Inventor
デニス キーフ，
デニス キーフ，
ハールド， ハンス デ
ハールド， ハンス デ
Original Assignee
シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド
シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド, シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド filed Critical シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド
Publication of JP2018517667A publication Critical patent/JP2018517667A/ja
Publication of JP2018517667A5 publication Critical patent/JP2018517667A5/ja
Application granted granted Critical
Publication of JP6797825B2 publication Critical patent/JP6797825B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2017552909A 2015-04-07 2016-04-07 気管支肺異形成症を治療する抗ｆｌｔ−１抗体 Active JP6797825B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562144247P 2015-04-07 2015-04-07
US62/144,247 2015-04-07
PCT/US2016/026436 WO2016164579A1 (en) 2015-04-07 2016-04-07 Anti-flt-1 antibodies in treating bronchopulmonary dysplasia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020191516A Division JP2021014473A (ja) 2015-04-07 2020-11-18 気管支肺異形成症を治療する抗ｆｌｔ−１抗体

Publications (3)

Publication Number Publication Date
JP2018517667A JP2018517667A (ja) 2018-07-05
JP2018517667A5 JP2018517667A5 (enExample) 2019-05-16
JP6797825B2 true JP6797825B2 (ja) 2020-12-09

Family

ID=55795198

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017552909A Active JP6797825B2 (ja) 2015-04-07 2016-04-07 気管支肺異形成症を治療する抗ｆｌｔ−１抗体
JP2020191516A Pending JP2021014473A (ja) 2015-04-07 2020-11-18 気管支肺異形成症を治療する抗ｆｌｔ−１抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020191516A Pending JP2021014473A (ja) 2015-04-07 2020-11-18 気管支肺異形成症を治療する抗ｆｌｔ−１抗体

Country Status (10)

Country Link
US (2) US10711065B2 (enExample)
EP (2) EP4063390A1 (enExample)
JP (2) JP6797825B2 (enExample)
CN (1) CN107683143A (enExample)
AU (3) AU2016246738B2 (enExample)
CA (1) CA2981961A1 (enExample)
HK (1) HK1249913A1 (enExample)
MA (1) MA41900A (enExample)
MX (1) MX2017012831A (enExample)
WO (1) WO2016164579A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7384815B2 (ja) * 2018-03-22 2023-11-21 ザ チルドレンズ メディカル センター コーポレーション 肺の修復に関する方法および組成物
CN113260628A (zh) * 2018-06-22 2021-08-13 夏尔人类遗传性治疗公司 治疗支气管肺发育不良的抗flt-1抗体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7335362B2 (en) 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
US7435419B2 (en) * 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
JP5650876B2 (ja) * 2002-07-19 2015-01-07 ベス・イスラエル・ディーコニス・メディカル・センター 子癇前症または子癇の診断方法および治療方法
EP2377555A3 (en) 2004-11-18 2011-11-23 Imclone LLC Antibodies against vascular endothelial growth factor receptor-1
US20060153835A1 (en) * 2005-01-12 2006-07-13 Smith Henry J Treatment of pre-eclampsia in pregnant women using targeted apheresis
US8349325B2 (en) 2008-12-23 2013-01-08 Abbott Laboratories Soluble FMS-like tyrosine kinase-1 (sFLT-1) antibody and related composition, kit, methods of using, and materials and method for making
CA2826563C (en) * 2011-02-07 2020-10-20 Paul Kussie Methods and systems for treating eclampsia and pre-eclampsia
CN104955843B (zh) * 2013-01-28 2019-08-13 夏尔人类遗传性治疗公司 治疗杜兴氏肌营养不良的抗flt-1抗体
TW201517916A (zh) 2013-03-15 2015-05-16 Lilly Co Eli Ｖｅｇｆｒ１抗體之治療用途

Also Published As

Publication number Publication date
US20180100017A1 (en) 2018-04-12
WO2016164579A1 (en) 2016-10-13
JP2021014473A (ja) 2021-02-12
HK1249913A1 (zh) 2018-11-16
US20210130475A1 (en) 2021-05-06
US10711065B2 (en) 2020-07-14
CN107683143A (zh) 2018-02-09
AU2024227035A1 (en) 2024-10-24
EP4063390A1 (en) 2022-09-28
EP3280735B1 (en) 2022-02-16
AU2022201781B2 (en) 2024-07-18
CA2981961A1 (en) 2016-10-13
AU2016246738A1 (en) 2017-10-26
JP2018517667A (ja) 2018-07-05
MX2017012831A (es) 2018-05-04
AU2016246738B2 (en) 2021-12-16
MA41900A (fr) 2021-06-02
AU2022201781A1 (en) 2022-04-07
BR112017021416A2 (pt) 2018-07-03
EP3280735A1 (en) 2018-02-14
AU2016246738A8 (en) 2017-12-21

Similar Documents

Publication Publication Date Title
AU2024227035A1 (en) Anti-flt-1 antibodies in treating bronchopulmonary dysplasia
KR20130136968A (ko) 안전하고 기능적인 인간화 항 베타-아밀로이드 항체
KR20190054160A (ko) 항-il-33 항체 및 그의 용도
JP2022040124A (ja) デュシェンヌ型筋ジストロフィーの治療における抗ｆｌｔ－１抗体
HUE035575T2 (en) Use of TGF-beta antagonists to treat children at risk of developing bronchopulmonary dysplasia
US20200362041A1 (en) Anti-flt-1 antibodies in treating bronchopulmonary dysplasia
EP1517703B1 (en) Placental growth factor as a target for the treatment of osteoporosis
JP2023108031A (ja) 気管支肺異形成症の治療における抗Ｆｌｔ－１抗体
CN120693177A (zh) 用于治疗胎儿和新生儿溶血性疾病的组合物和方法
CA2982815C (en) Anti-flt-1 antibodies in treating bronchopulmonary dysplasia
BR112017021416B1 (pt) Uso de um anticorpo anti-flt-1 ou seu fragmento de ligação ao antígeno
RU2847150C1 (ru) Применение антагониста il-18 для лечения и/или предупреждения атопического дерматита или связанного с ним состояния
HK40112898A (en) Anti-alk1 antibodies and methods of using the same
KR20220059888A (ko) 신규 항-Tie2 항체 또는 이의 항원 결합 단편, 및 이의 용도

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190404

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190404

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200612

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201020

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201118

R150 Certificate of patent or registration of utility model

Ref document number: 6797825

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250